APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

ID#: NCT03615235

Age: Birth - 66+

Gender: All

Healthy Subjects: No

Recruitment Status: Recruiting

Start Date: May 16, 2019

End Date: September 01, 2023

Contact Information:
Laurie P. Russell, MS
336-713-4292
Carrie Smith
336-713-7531
Summary: The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
Eligibility: Inclusion Criteria for Living Donors:

- Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion. Exclusion Criteria for Living Donors:

- Participants who are unable or unwilling to provide informed consent. Inclusion Criteria for Recipients:

- Recipients of a kidney transplant from an eligible living or deceased donor with recent African ancestry.

- Recipients of multi-organ transplants including a kidney plus an additional organ (i.e. liver, heart, lung, pancreas, etc.) or pediatric en bloc and dual kidney transplants. Exclusion Criteria for Recipients:

- Participants who are unable or unwilling to provide informed consent.
Find a Clinical Trial